NIAID

Global Camps Africa Honors Dr. Anthony Fauci with Prestigious Sizanani Award

Retrieved on: 
월요일, 4월 22, 2024
Infection, Public, Heart, Research, PEPFAR, HIV/AIDS, NIAID, Disease, MSNBC

WASHINGTON, April 22, 2024 /PRNewswire/ -- Global Camps Africa is pleased to announce that Dr. Anthony Fauci, renowned immunologist and public health advocate, was honored with the Sizanani Award at its annual gala event in Washington, DC on April 20th.

Key Points: 
  • WASHINGTON, April 22, 2024 /PRNewswire/ -- Global Camps Africa is pleased to announce that Dr. Anthony Fauci, renowned immunologist and public health advocate, was honored with the Sizanani Award at its annual gala event in Washington, DC on April 20th.
  • The Sizanani Award, which translates from Zulu to mean "help each other," embodies the heart of Global Camps Africa's mission to empower children in the global battle against HIV/AIDS.
  • The award was presented by MSNBC anchor Lawrence O'Donnell, previous Sizanani Award recipient and supporter of Global Camps Africa's work.
  • I applaud the ingenuity of the founder of Global Camps Africa, Philip Lilienthal, for his extraordinary vision," said Dr. Fauci on accepting the award .

SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIA

Retrieved on: 
목요일, 4월 18, 2024
Chlamydia trachomatis, FDA, Mortality, Administration, Pelvic inflammatory disease, Malaria, Death, Doctor of Philosophy, Vaccine, Development, Point-of-care testing, PHAC, Diagnosis, Gonorrhea, Novo Nordisk Foundation, Prevalence, HHS, Vertical loop, Neonatal sepsis, Infertility, OTC, Public Health Agency, Entrepreneurship, Infection, Urine, Neisseria gonorrhoeae, Patient, Ng, CARB-X, NIH, Education, BMBF, STI, Therapy, Disease, Bangladesh Technical Education Board, SARS-CoV-2, HIV/AIDS, Social work, NIAID, Bill, Physician

BOSTON, April 18, 2024 /PRNewswire/ -- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.

Key Points: 
  • STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.
  • Additionally, STI Scout can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility.
  • STI Scout uses the Scout Hub to run and the Scout Connect mobile app, which provides instructions, tracks results, and eventually will allow patients to connect digitally to a healthcare provider.
  • Scout's diagnostic is the second diagnostic and ninth project to receive a CARB-X award as part of the 2022-2023 funding call .

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

Retrieved on: 
화요일, 4월 2, 2024
Stargardt disease, Disease, Safety, Webcast, Inflammation, Patient, CGMP, Data, Inhalation, Cohort, RP, Life, Bank statement, Investment, Clinical trial, NIAID, Injection, AMD, Vaccine, Nextgen, Geographic atrophy, RHO, FDA, Lipid metabolism, Government, Oxidative stress, Pharmaceutical industry

Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively

Key Points: 
  • Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively
    MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today provided a general business update with certain financials for the year ending 2023.
  • During the fourth quarter of 2023, the Company announced its mucosal vaccine candidate, OCU500, was chosen for the multi-billion-dollar NIAID Project NextGen initiative.
  • The first patient was dosed in the Phase 1/2 trials to assess the safety and efficacy of OCU410ST for Stargardt disease in November 2023.
  • Ocugen’s cash, cash equivalents, and investments totaled $39.5 million as of December 31, 2023, compared to $90.9 million as of December 31, 2022.

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

Retrieved on: 
목요일, 3월 28, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Radiation, Acute radiation syndrome, Attack, ARS, Inflammation, Education, Chronic obstructive pulmonary disease, RNCP, USUHS, Virus, IND, European Medicines Agency, Outline of health sciences, Nausea, Accident, Hypoxia (medical), NIAID, Defense Threat Reduction Agency, AFRRI, HIE, Vaccine, Collection, Vomiting, Food, FDA, Defense, Infection, Peptide, Pharmaceutical industry

“We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.

Key Points: 
  • “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
  • AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
  • It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
  • ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.

Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer

Retrieved on: 
목요일, 3월 28, 2024
Internal medicine, University, Natural science, Biomedicine, Alphabet, Calico (company), Immune system, SAN, Research, Science, Whitehead Institute, National academy, Biology, Biochemistry, Johns Hopkins University, NIAID, Most, Nobel, Bangladesh Technical Education Board, Birth, Biomedical Research, O.B.E, Infection, Ageing, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.
  • Dr. Lenardo is an accomplished molecular immunologist and geneticist whose medical research career spans four decades.
  • "Securing someone of Mike's caliber for the critical role of Chief Scientific Officer is a major achievement for Calico," said Dr. Levinson, CEO of Calico.
  • "The commitment to scientific excellence and integrity at Calico, coupled with the highly talented team, is truly impressive and reflected in the impactful progress they are making.

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
수요일, 3월 6, 2024
Infection, Chair, Bangladesh Technical Education Board, Mental health, Injection (medicine), University of Alabama, Rilpivirine, Fungal infection, NIAID, Arm, CROI, PWH, Quality of life, ACTG, Johnson & Johnson, Data monitoring committee, Conference, Health, University, ART, UM1, Male, DSMB, ViiV Healthcare, HIV, Failure, University of North Carolina, Vaccine

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.

ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination

Retrieved on: 
수요일, 3월 6, 2024
Infection, Bangladesh Technical Education Board, CD4, Superior, Hepatitis B, Headache, CpG, Fungal infection, NIAID, CROI, ACTG, University of Cincinnati, Weill Cornell Medicine, Conference, Vaccination, University, ART, Fatigue, Virus, Myalgia, White, Black, Protocol, UM1, Massachusetts General Hospital, Male, Hepatitis, HIV, University of North Carolina, Vaccine

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

Key Points: 
  • These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.
  • People living with HIV, especially those with lower CD4 counts, often do not develop protective antibodies after receiving conventional hepatitis B vaccines.
  • The HepB-CpG (HEPLISAV-B®) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who have not responded to conventional hepatitis B vaccines.
  • “Hepatitis B remains a significant issue for people living with HIV, as having both viruses increases the likelihood of liver complications,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV

Retrieved on: 
화요일, 3월 5, 2024
Infection, Liver, Bangladesh Technical Education Board, Metabolism, Woman, P.T, Fungal infection, NIAID, Prediabetes, CROI, Liver injury, Inflammation, Quality of life, ACTG, ALT, Weight loss, Waist, Weight, Organ dysfunction, University of Southern California, Conference, Health, Glucagon-like peptide-1 receptor, University, SLIM, ART, Triglyceride, BMI, UM1, Insulin resistance, HIV, Non-alcoholic fatty liver disease, Research, University of North Carolina, Dietary supplement

Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.

Key Points: 
  • Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.
  • Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.
  • SLIM LIVER is the first study evaluating semaglutide as a treatment for MASLD among people living with HIV.
  • MASLD is common among people living with HIV and likely acts synergistically with HIV to accelerate liver injury and organ dysfunction.

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
월요일, 3월 4, 2024
Infection, Chairperson, Bangladesh Technical Education Board, Diabetes, CMV, Metabolism, Merck, Cancer, Endothelial dysfunction, Fungal infection, NIAID, CROI, Inflammation, Blood, IL-6, Ageing, ACTG, Splenic infarction, Risk, Conference, Cytomegalovirus, University, ART, Biomarker, Merck & Co., University of California, UM1, Insulin resistance, Poster, Letermovir, Probability, Atherosclerosis, Plasma, TNF, HIV, University of North Carolina, Immune system, Brain

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 2월 29, 2024
Vaccine, Project, Webcast, Exosome, Protein, Poster, Mouse, Infection, Liver, Bangladesh Technical Education Board, Biotechnology, NIAID, Marketing, File, BLA, Therapy, Congress, PPMD, PUL, WMS, CMC, Distribution, International, Regenerative medicine, ID, Duchenne muscular dystrophy, Safety, Dicarboxylic acid, Biologics license application, IND, Commercialization, SARS-CoV-2, Lipid, Messenger, MicroRNA, Inflammation, FDA, Food, DMD, Priority review, Cell, COVID-19, Report, Patient, Oligonucleotide, PRV, Kidney, Tissue, Pharmaceutical industry

Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.

Key Points: 
  • Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.
  • Next steps for Cohort A: plan to report top-line data in the fourth quarter of 2024.
  • Revenues for the fourth quarter of 2023 were approximately $12.1 million compared with approximately $1.0 million for the fourth quarter of 2022.
  • Operating expenses: Total operating expenses for the fourth quarter of 2023 were approximately $13.2 million compared with approximately $9.0 million for the fourth quarter of 2022.